{"id":31852,"date":"2025-04-15T14:58:20","date_gmt":"2025-04-15T06:58:20","guid":{"rendered":"https:\/\/flcube.com\/?p=31852"},"modified":"2025-04-15T14:58:21","modified_gmt":"2025-04-15T06:58:21","slug":"jiangsu-nhwa-initiates-phase-i-trial-for-nh280105-an-oral-lp-pla%e2%82%82-inhibitor-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31852","title":{"rendered":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer’s Disease"},"content":{"rendered":"\n

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262<\/a>) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer’s disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.<\/p>\n\n\n\n

Mechanism of Action<\/strong>
NH280105 targets Lp-PLA\u2082 (lipoprotein-associated phospholipase A\u2082), an enzyme linked to low-density lipoprotein (LDL) that plays a critical role in promoting inflammation in cardiovascular and neurological tissues. By inhibiting Lp-PLA\u2082, NH280105 effectively reduces inflammation and repairs the physiological function of the blood-brain barrier (BBB). This mechanism helps reduce the deposition of pathological biomarkers such as A\u03b2 plaques, potentially improving cognitive function in patients with Alzheimer’s disease. Its unique approach positions NH280105 as a promising new option in the evolving landscape of AD therapy.<\/p>\n\n\n\n

Clinical Study Design<\/strong>
The Phase I study, conducted at CMAX in Australia, is designed to evaluate the safety, tolerability, and pharmacokinetics of NH280105 in healthy adult subjects. The trial will assess both single and multiple oral doses and explore the effects of food interactions on the drug\u2019s absorption and systemic exposure. These data will provide essential support for the drug\u2019s subsequent clinical development stages.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase…<\/p>\n","protected":false},"author":1,"featured_media":31854,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1472,1471],"class_list":["post-31852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-nhwa-pharmaceutical","tag-she-002262"],"yoast_head":"\nJiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer's disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31852\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer's disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31852\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T06:58:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T06:58:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer’s Disease\",\"datePublished\":\"2025-04-15T06:58:20+00:00\",\"dateModified\":\"2025-04-15T06:58:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1512-png.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Nhwa Pharmaceutical\",\"SHE: 002262\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31852#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31852\",\"name\":\"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1512-png.webp\",\"datePublished\":\"2025-04-15T06:58:20+00:00\",\"dateModified\":\"2025-04-15T06:58:21+00:00\",\"description\":\"China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer's disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31852\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1512-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1512-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31852#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer’s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease - Insight, China's Pharmaceutical Industry","description":"China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer's disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31852","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease","og_description":"China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer's disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.","og_url":"https:\/\/flcube.com\/?p=31852","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T06:58:20+00:00","article_modified_time":"2025-04-15T06:58:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31852#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31852"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer’s Disease","datePublished":"2025-04-15T06:58:20+00:00","dateModified":"2025-04-15T06:58:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31852"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31852#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp","keywords":["Clinical trial approval \/ initiation","Nhwa Pharmaceutical","SHE: 002262"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31852#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31852","url":"https:\/\/flcube.com\/?p=31852","name":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31852#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31852#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp","datePublished":"2025-04-15T06:58:20+00:00","dateModified":"2025-04-15T06:58:21+00:00","description":"China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase I clinical study for its investigational drug NH280105, an oral Lp-PLA\u2082 inhibitor for the treatment of Alzheimer's disease (AD). The first subject has been enrolled and dosed, marking a significant milestone in the development of this novel therapeutic candidate.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31852#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31852"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31852#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp","width":1080,"height":608,"caption":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer's Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31852#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA\u2082 Inhibitor for Alzheimer’s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1512-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31852"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31852\/revisions"}],"predecessor-version":[{"id":31855,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31852\/revisions\/31855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31854"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}